000829453 001__ 829453
000829453 005__ 20210129230304.0
000829453 0247_ $$2doi$$a10.1080/14737140.2017.1302799
000829453 0247_ $$2ISSN$$a1473-7140
000829453 0247_ $$2ISSN$$a1744-8328
000829453 0247_ $$2WOS$$aWOS:000399904100001
000829453 037__ $$aFZJ-2017-03152
000829453 041__ $$aEnglish
000829453 082__ $$a610
000829453 1001_ $$0P:(DE-Juel1)143792$$aGalldiks, Norbert$$b0$$eCorresponding author$$ufzj
000829453 245__ $$aAmino acid PET in neuro-oncology: applications in the clinic
000829453 260__ $$aAbingdon, Oxon$$bTaylor & Francis$$c2017
000829453 3367_ $$2DRIVER$$aarticle
000829453 3367_ $$2DataCite$$aOutput Types/Journal article
000829453 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1492775633_23540
000829453 3367_ $$2BibTeX$$aARTICLE
000829453 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000829453 3367_ $$00$$2EndNote$$aJournal Article
000829453 520__ $$aFor more than three decades, radiolabeled amino acids have been used in the field of neuro-oncology. The most experience for this class of positron emission tomography (PET) tracers has been gained with 11C-methyl-l-methionine (MET). MET is labeled with the positron-emitting isotope carbon-11, which has a short half-life of 20 min. Thus, the use of MET is restricted to PET centers with an on-site cyclotron unit. This prompted the development of amino acid tracers labeled with positron emitters that have longer half-lives. More recently, O-(2-[18F]fluoroethyl)-l-tyrosine (FET) was developed and is a 18F-labeled amino acid tracer with a half-life of 110 min, resulting in a higher practicability compared to MET. The use of FET has grown rapidly in recent years, especially in Western Europe, and has led to a replacement of MET by the more convenient FET. The improved availability has led to several thousand FET PET scans being performed in some centers. Furthermore, clinical results with PET using FET and MET seem to be comparable [1 Grosu AL, Astner ST, Riedel E, et al. An interindividual comparison of O-(2- [(18)F]fluoroethyl)-L-tyrosine (FET)- and L-[methyl-(11)C]methionine (MET)-PET in patients with brain gliomas and metastases. Int J Radiat Oncol Biol Phys. 2011;81(4):1049–1058.[CrossRef], [PubMed], [Web of Science ®], [Google Scholar]]. The 18F-labeled amino acid analogue 3,4-dihydroxy-6-[18F]-fluoro-l-phenylalanine (FDOPA) – primarily developed to evaluate dopamine synthesis in patients with movement disorders – is also increasingly being used for brain tumor imaging [2 Herrmann K, Czernin J, Cloughesy T, et al. Comparison of visual and semiquantitative analysis of 18F-FDOPA-PET/CT for recurrence detection in glioblastoma patients. Neuro Oncol. 2014;16(4):603–609.[CrossRef], [PubMed], [Web of Science ®], [Google Scholar]]. However, in the USA, the standard tracer for tumor imaging 18F-2-fluoro-2-deoxy-d-glucose (FDG) PET is still frequently used in brain tumor patients, although the evaluation of brain tumors using FDG is difficult because levels of glucose metabolism in healthy brain parenchyma are usually high. This leads to a poor tumor-to-background contrast compared with amino acid tracers [3 Albert NL, Weller M, Suchorska B, et al. Response assessment in neuro-oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas. Neuro Oncol. 2016;18(9):1199–1208.[CrossRef], [PubMed], [Web of Science ®], [Google Scholar]].
000829453 536__ $$0G:(DE-HGF)POF3-573$$a573 - Neuroimaging (POF3-573)$$cPOF3-573$$fPOF III$$x0
000829453 588__ $$aDataset connected to CrossRef
000829453 7001_ $$0P:(DE-Juel1)131777$$aLangen, Karl-Josef$$b1$$ufzj
000829453 773__ $$0PERI:(DE-600)2090850-7$$a10.1080/14737140.2017.1302799$$gp. 1 - 3$$n5$$p395-397$$tExpert review of anticancer therapy$$v17$$x1744-8328$$y2017
000829453 8564_ $$uhttps://juser.fz-juelich.de/record/829453/files/Amino%20acid%20PET%20in%20neuro%20oncology%20applications%20in%20the%20clinic.pdf$$yRestricted
000829453 8564_ $$uhttps://juser.fz-juelich.de/record/829453/files/Amino%20acid%20PET%20in%20neuro%20oncology%20applications%20in%20the%20clinic.gif?subformat=icon$$xicon$$yRestricted
000829453 8564_ $$uhttps://juser.fz-juelich.de/record/829453/files/Amino%20acid%20PET%20in%20neuro%20oncology%20applications%20in%20the%20clinic.jpg?subformat=icon-1440$$xicon-1440$$yRestricted
000829453 8564_ $$uhttps://juser.fz-juelich.de/record/829453/files/Amino%20acid%20PET%20in%20neuro%20oncology%20applications%20in%20the%20clinic.jpg?subformat=icon-180$$xicon-180$$yRestricted
000829453 8564_ $$uhttps://juser.fz-juelich.de/record/829453/files/Amino%20acid%20PET%20in%20neuro%20oncology%20applications%20in%20the%20clinic.jpg?subformat=icon-640$$xicon-640$$yRestricted
000829453 8564_ $$uhttps://juser.fz-juelich.de/record/829453/files/Amino%20acid%20PET%20in%20neuro%20oncology%20applications%20in%20the%20clinic.pdf?subformat=pdfa$$xpdfa$$yRestricted
000829453 909CO $$ooai:juser.fz-juelich.de:829453$$pVDB
000829453 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)143792$$aForschungszentrum Jülich$$b0$$kFZJ
000829453 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131777$$aForschungszentrum Jülich$$b1$$kFZJ
000829453 9131_ $$0G:(DE-HGF)POF3-573$$1G:(DE-HGF)POF3-570$$2G:(DE-HGF)POF3-500$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bKey Technologies$$lDecoding the Human Brain$$vNeuroimaging$$x0
000829453 9141_ $$y2017
000829453 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000829453 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEXPERT REV ANTICANC : 2015
000829453 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000829453 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000829453 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000829453 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000829453 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000829453 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000829453 915__ $$0StatID:(DE-HGF)0550$$2StatID$$aNo Authors Fulltext
000829453 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000829453 9201_ $$0I:(DE-Juel1)INM-3-20090406$$kINM-3$$lKognitive Neurowissenschaften$$x0
000829453 9201_ $$0I:(DE-Juel1)INM-4-20090406$$kINM-4$$lPhysik der Medizinischen Bildgebung$$x1
000829453 9201_ $$0I:(DE-82)080010_20140620$$kJARA-BRAIN$$lJARA-BRAIN$$x2
000829453 980__ $$ajournal
000829453 980__ $$aVDB
000829453 980__ $$aUNRESTRICTED
000829453 980__ $$aI:(DE-Juel1)INM-3-20090406
000829453 980__ $$aI:(DE-Juel1)INM-4-20090406
000829453 980__ $$aI:(DE-82)080010_20140620